GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OSTO:BIOA B) » Definitions » Loans Receivable

BioArctic AB (OSTO:BIOA B) Loans Receivable : kr0.0 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BioArctic AB Loans Receivable?

BioArctic AB's Loans Receivable for the quarter that ended in Mar. 2024 was kr0.0 Mil.


BioArctic AB Loans Receivable Historical Data

The historical data trend for BioArctic AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Loans Receivable Chart

BioArctic AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

BioArctic AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioArctic AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


BioArctic AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of BioArctic AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BioArctic AB (OSTO:BIOA B) Business Description

Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB (OSTO:BIOA B) Headlines

No Headlines